Terminated PHASE2 INTERVENTIONAL 1-arm NCT01135758

Study of Depression-Ketamine-Brain Function

Pilot Study Probing the Antidepressant Effects of 0.5 mg/kg Intravenous Ketamine in Drug-resistant Depressed Patients (Unipolar Depression): Efficacy, Safety, Brain Function

Sponsor: Markus KOSEL

Conditions Major Depression

Interventions Ketamine

Updated 5 times since 2017 Last updated: Dec 4, 2015 Started: Jun 30, 2010 Primary completion: Jun 30, 2015 Completion: Sep 30, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

End of funding of study

This PHASE2 trial investigates Major Depression and is currently terminated or withdrawn. Markus KOSEL leads this study, which shows 5 recorded versions since 2010 — indicating limited longitudinal coverage. This study adds to the longitudinal dataset for psychiatric treatment development.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Jun 2010

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Markus KOSEL

Data source: University Hospital, Geneva

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Geneva, Switzerland